Anticancer agent 242

• Description:

  Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC50 = 0.55 μM, breast adenocarcinoma) [1].

• UNSPSC:

  12352005

• Target:

  Biochemical Assay Reagents

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/anticancer-agent-242.html

• Smiles:

  FC1=C(F)C(SCCC2=CC=C(C(N3CCN(C(C4=CC=CC=C4C5=C(C=C/6)C(OC7=C5C=CC(N(CC)CC)=C7)=CC6=[N+](CC)\CC)=O)CC3)=O)C=C2)=C(F)C(NC8CCCCCCCCCCC8)=C1S(=O)(N)=O.[Cl-]

• Molecular Formula:

  C59H72ClF3N6O5S2

• Molecular Weight:

  1101.82

• References & Citations:

  [1]Niels V Heise, et al. Dehydroabietylamine-substituted trifluorobenzene sulfonamide rhodamine B hybrids as anticancer agents overcoming drug resistance. Eur J Med Chem. 2024 Jul 10:276:116667.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [9007-83-4]